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Ubiquitination of core stem cell transcription factors can directly affect stem cell maintenance and differentiation. Ubiquitination
and deubiquitination must occur in a timely and well-coordinated manner to regulate the protein turnover of several stemness
related proteins, resulting in optimal embryonic stem cell maintenance and differentiation.There are two switches: an E3 ubiquitin
ligase enzyme that tags ubiquitinmolecules to the target proteins for proteolysis and a second enzyme, the deubiquitinating enzyme
(DUBs), that performs the opposite action, thereby preventing proteolysis. In order to maintain stemness and to allow for efficient
differentiation, both ubiquitination and deubiquitination molecular switches must operate properly in a balanced manner. In this
review, we have summarized the importance of the ubiquitination of core stem cell transcription factors, such as Oct3/4, c-Myc,
Sox2, Klf4, Nanog, and LIN28, during cellular reprogramming. Furthermore, we emphasize the role of DUBs in regulating core
stem cell transcriptional factors and their function in stem cell maintenance and differentiation. We also discuss the possibility
of using DUBs, along with core transcription factors, to efficiently generate induced pluripotent stem cells. Our review provides
a relatively new understanding regarding the importance of ubiquitination/deubiquitination of stem cell transcription factors for
efficient cellular reprogramming.
1. Introduction
Pluripotent stem cells, which are derived from the inner cell
mass (ICM) of the blastocyst, are characterized by unlimited
self-renewal and they can be triggered to differentiate into all
three embryonic germ layers: (i) ectoderm, skin and nerve;
(ii) mesoderm, bone, blood, and muscle; and (iii) endoderm,
gut and lung tissues. In 1998, the first human embryonic stem
cells (hESCs) derived from the ICM of a preimplantation
blastocyst were isolated [1]. Thereafter, several human ES cell
lines became available to researchers for the generation of
cells of multiple lineages [2]. Thus, the capacity to culture
embryonic stem cells and induce them into different cell
types under defined in vitro conditions has revolutionized
developmental biology [3].
2. Induced Pluripotent Stem Cells
Induced pluripotent stem cells are defined as differentiated
cells that have been experimentally reprogrammed to an
embryonic stem cell- (ESC-) like state. In 2006, Yamanaka’s
group announced that adult skin cells could be directly
reprogrammed to become pluripotent stem cells using a
combination of only four genes. They initially started with
a list of 24 known pluripotency-associated genes expressed
in ES cells. Ultimately, they succeeded in reprogramming
mouse adult fibroblasts to an embryonic-like state using a
cocktail of just four transcription factors, including octamer
3/4 (Oct3/4), SRYbox-containing gene 2 (Sox2), Kru¨ppel-like
factor 4 (Klf4), and c-Myc [4]. The final reprogrammed cells
were termed induced pluripotent stem cells (iPSCs). Later,
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two different research groups were able to effectively generate
iPSCs from human somatic cells using slightly different com-
binations of genes, including Oct3/4, Sox2, Nanog, and
LIN28A (LIN28) [5, 6]. Other scientists have been successful
in generating iPSCs from fibroblasts [7], leukocytes [8],
neural stem cells [9], hepatocytes [10], keratinocytes [11], pan-
creas cells [12], and cord blood cells [13]. Subsequently, repro-
gramming technology was successfully used to derive plu-
ripotent cells from various other species, including the rhesus
monkey [14], rat [15], cow [16], dog [17], sheep [18], goat [19],
pig [20], horse [21], and buffalo [22].
In recent years, several methods have been successfully
established for the generation of iPSCs, including virally
induced iPSCs [12, 23–25], and nonvirally derived iPSCs
using episomal vectors [26], minicircle vectors [27, 28], small
molecules [29–33], transposon systems [34–37],mRNAs [38–
40], microRNAs [41–44], and reprogramming proteins [45,
46]. However, it is worth mentioning that there are several
hurdles that need to be overcome in order to develop safe
iPSC technology for clinical trials. Lentiviral or retroviral
vectors have the ability to integrate their transgene into the
host genome.These transcriptionally silent proviruses can be
reactivated at any time leading to oncogenesis. Adenoviral
or episomal vectors facilitate transient expression of repro-
gramming factors without genomic integration. However,
the reprogramming efficiency using episomal vectors is low
and not completely free from the pitfalls of chromosomal
disruption [47–49].
Among the experimental methods studied, transgene-
free iPSC generation using reprogramming transcription
factors has its own advantages and disadvantages. Generation
of iPSCs by direct delivery of reprogramming proteins is a
safe method that can be used for clinical trials. However, the
reprogramming proteins are highly unstable and the repro-
gramming efficiency is low. Consequently, treatment with
protein factors has to be performed repeatedly. This might
lead to differences in reproducibility and is not an economical
method. Thus, in this review we have attempted to compile
available data in an effort to understand the importance of the
ubiquitination and deubiquitination processes, which take
place in core stem cell transcription factors and their appli-
cation in developing an efficient method for cellular repro-
gramming.
3. Ubiquitin Proteasome Pathway
Ubiquitination is a process through which ubiquitin mol-
ecules are attached to protein substrates for protein degrada-
tion. It is one of the most important posttranslational mod-
ifications (PTMs) regulating the stability and functional
activity of proteins.Theubiquitination process is orchestrated
by a cascade of enzymes consisting of ubiquitin-activating
enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiq-
uitin ligases (E3) that mediate transfer of ubiquitin molecules
onto targeted protein substrates [50–52].
Ubiquitin conjugation initiates with the activation of a
ubiquitin molecule by the E1 enzyme. During this process,
an ATP-dependent thiol ester bond is formed between the
C-terminus of the ubiquitin molecule and the active cysteine
site of the E1 enzyme. Subsequently, ubiquitin is transferred
to the E2 enzyme through a thioester linked E2-ubiquitin
intermediate. Next, the E3 enzyme identifies and recruits the
targeted substrate protein, interacts with the E2-ubiquitin
intermediate, and catalyzes the transfer of ubiquitin to a
lysine residue on the targeted protein. Finally, polyubiqui-
tinated protein substrates are subjected to ATP-dependent
hydrolysis by the 26S proteasome [50] (Figure 1).
Ubiquitin is a small molecule that attaches to protein
substrates as a monomer or as polymers. Ubiquitin contains
seven lysine residues within its sequence, lysine-6, lysine-11,
lysine-27, lysine-29, lysine-33, lysine-48, and lysine-63, each
of which can be utilized for the formation of ubiquitin-
ubiquitin linkages called polyubiquitin chains [53]. Monou-
biquitination occurs when a single ubiquitin molecule is
attached to one lysine residue within the substrate, while pol-
yubiquitination is the process through which a chain of
ubiquitin molecules is attached to a specific lysine residue
within the substrate. Usually, monoubiquitination of a pro-
tein serves as a signal for DNA repair, vesicle sorting, signal
transduction, and receptor endocytosis [54–57], whereas pol-
yubiquitination is mainly restricted to protein degradation
and signal transduction [58].
Ubiquitin chains are arranged in several different ways,
which lead to distinct outcomes for the specific substrate.
For instance, monoubiquitination and lysine-63 polyubiqui-
tination have been linked to regulating protein activation or
signal transduction. Lysine-6 and lysine-48 polyubiquitina-
tion target proteins for proteasomal degradation [59]. Several
types of polyubiquitination and their cellular functions are
illustrated in Figure 2. However, the ubiquitination process
regulates several biological processes, such as cell cycle
control, oncogenesis, immune response, transcriptional reg-
ulation, embryonic development, apoptosis, preimplantation,
and intracellular signaling pathways [50].
4. Deubiquitination
The process of cleaving ubiquitin molecules from ubiquitin-
conjugated protein substrates by deubiquitinating enzymes
(DUBs) is called deubiquitination. As every action provokes
a reaction, all the major posttranslational modifications,
including the ubiquitination process, can be reversed. Protein
ubiquitination catalyzed by E3 ligases can be reversed by
DUBs to prevent protein degradation. DUBs bind to the
ubiquitin-based isopeptide bond, thus counteracting ubiq-
uitin-protein ligase activity (Figure 3).
4.1. Deubiquitinating Enzymes and Their Classification.
DUBs belong to a large family of proteases that reverse
protein ubiquitination, which is an important process for
maintaining cell homeostasis. DUBs can be divided into six
families: (i) ubiquitin C-terminal hydrolases (UCH), (ii)
ubiquitin specific processing proteases (USP), (iii) Jab1/Pab1/
MPN domain-containing metalloenzymes (JAMM), (iv)
Otu-domain ubiquitin aldehyde-binding proteins (OTU), (v)
Ataxin-3/Josephin, and (vi) monocyte chemotactic protein-
induced proteases (MCPIPs). Among these, USPs are the
largest family, consisting of more than 50 members, each
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Figure 1: The ubiquitin proteasome system. The process of ubiquitination is catalyzed by an organized milieu of E1, E2, and E3 enzymes,
which promote the ligation of a ubiquitin molecule to the lysine residues in the protein substrates. Lysine-48-linked polyubiquitination chain
attached proteins are targeted to the 26S proteasome for protein degradation. DUB enzymes are involved in reversing ubiquitin conjugation
and in the recycling of ubiquitin molecules through the ubiquitin proteasome pathway.
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Figure 2: Ubiquitinmodifications and their cellular functions.The attachment of ubiquitinmolecules to one ormore lysine residues results in
polyubiquitination. Several types of polyubiquitin chains linked via lysine residues on the protein substrate are implicated in diverse cellular
functions.
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Figure 3: The ubiquitination and deubiquitination processes. A
ubiquitin E3 ligase enzyme catalyzes the transfer of ubiquitin to
lysine residue on the targeted protein and channels the protein to the
26S proteasome for protein degradation. Another class of enzyme,
called deubiquitinating enzymes, that is able to reverse ubiquitin
conjugation from protein substrates, thereby preventing proteolysis.
containing conserved domains and catalytic sites [50, 60–
65]. The major cellular functions of DUBs are (i) processing
of ubiquitin precursors, (ii) recycling ubiquitin molecules
during ubiquitination, (iii) editing of ubiquitin chains, and
(iv) reversal of ubiquitin conjugation [50, 66]. Thus, DUBs
play a critical role in the regulation of the proteasomal path-
way.
DUBs regulate a variety of cellular functions, such as the
prevention of protein degradation, proteasome or lysosome
dependent protein degradation, apoptosis, cell cycle pro-
gression, chromosome segregation, gene expression, DNA
repair, kinase activation, and localization and degradation of
signaling intermediates [50, 63–66]. However, DUB activity
and specificity are determined by protein-protein interac-
tions between protein complexes associated with DUBs,
subcellular localization, alterations in their expression levels,
and their differential activities in the various phases of the cell
cycle [50, 66].
5. Reprogramming Somatic
Cells to Pluripotency Using Core
Transcriptional Factors
Pluripotent ESCs have the capacity to differentiate into sev-
eral distinct cell lineages present in adult mammals. The
status of pluripotency in ESCs is regulated by a few stem cell
transcription factors. Among these transcriptional factors, a
combination of core transcriptional factors, including Oct3/
4, Sox2, c-Myc, Klf4, Nanog, and LIN28, has been proven to
reprogram somatic cells into induced pluripotent stem cells
[4, 5, 23, 67].
ThePOU transcription factorOct3/4 has been found to be
the most important Yamanaka factor in ES cell pluripotency
and in the generation of iPSCs [68–70]. Oct3/4 expression
appears in the early four- to eight-cell stage and declines as
cells start to undergo differentiation into multiple lineages.
The expression level of Oct3/4 plays a critical role in main-
taining the pluripotent state of ES cells. A twofold higher than
normal level of Oct3/4 expression induces ES differentiation
into bothmesoderm and endoderm [71] and a 1.5-fold higher
than normal level in germ cells results in gonadal tumors
[72]. Elevated levels of Oct3/4 alone can directly reprogram
CD34+ cells intomesoderm progenitor cells ormesenchymal
stem cells [73].
Sox2 is a member of a large protein family, characterized
by their structure and sequence homology to the Sry (sex-
determining region of chromosome Y) protein. Sox2 is
considered to be a master regulator of both iPSCs and neural
stem cells (NSCs). Sox2 has the potential to reestablish plu-
ripotency in somatic cells by reprogramming them to iPSCs
[4]. Increasing Sox2 levels in ESCs induces differentiation
into the neural lineage [74, 75]. Interestingly, a recent report
demonstrated that Sox2 alone is sufficient to directly repro-
gram fibroblasts into multipotent NSCs [76].
Klf4 is one of the Yamanaka transcription factors, suffi-
cient to generate pluripotent stem cells from normal fibrob-
last cells [4]. However, although Klf4 alone is insufficient to
induce reprogramming, it is essential for the generation of
high quality iPSCs. Indeed, use of Klf4 results in the ability
to generate iPSCs that are able to form high-contribution
chimeras or efficiently generate “all-iPSC mice” by tetraploid
(4n) complementation [77]. Klf4 acts as an upstream regula-
tor of a large feed-forward loop that includes Oct3/4, Sox2, c-
Myc, and Nanog, indicating the existence of a transcriptional
hierarchy within the four reprogramming factors with both
autoregulatory and feed-forward regulation. In addition, Klf4
enhances the core transcriptional network of iPSCs or ESCs
and is also involved in mediating higher-order chromatin
structure for the maintenance and induction of pluripotency.
c-Myc is considered to be a reprogramming inducer
involved in the direct activation of pluripotent marker genes
and in themaintenance of pluripotency inmouse ES cells [4].
c-Myc has been reported to be a universal amplifier of existing
gene expression in lymphocytes, ESCs, and tumor cells
through its accumulation on the promoter regions of active
genes and also causes transcriptional amplification [78, 79].
However, c-Myc is avoided during reprogramming of cells
due to its oncogenic behavior, which may lead to reactivation
of Myc in progeny iPSCs, causing tumor formation [68, 80].
Nanog was initially reported to be the ENK gene (early
embryo-specific NK) whose expression was specific to ES
cells [81]. Later it was renamed Nanog by two independent
groups [82, 83]. The expression of Nanog is confined to the
inner cell mass of human blastocysts [84]. It is expressed at
high levels in embryonic carcinoma cells and undifferentiated
ESCs, and its expression level decreases upon ESC differenti-
ation [82, 85]. A loss of pluripotency was reported in Nanog-
deficient ESCs [86, 87], suggesting the importance of Nanog
in maintenance of ES cell pluripotency.
Nanog was found to enhance reprogramming kinetics
when it was included along with the Yamanaka factors during
reprogramming of cells [67]. Nanog can enhance fusion-
based reprogramming and also mouse epiblast stem cell
reprogramming [88, 89]. Nanog is not required for the early
stages of iPSC generation but is necessary for the final
transition from the pre-iPSC state to the fully induced ground
state [89]. Additionally, Esrrb, a direct downstream target of
Nanog, has been found to be involved in the transition of pre-
iPSCs to the pluripotent ground state [90].
LIN28 is also a reprogramming factor that, along with
Oct3/4, Sox2, and Nanog, is able to successfully reprogram
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Figure 4: Schematic representation of the human Oct3/4, Sox2, Klf4, c-Myc, and Nanog proteins. Shown are the locations of both predicted
and reported lysine sites for ubiquitination (lysine sites are predicted using the bioinformatics tool http://www.ubpred.org/).
human somatic fibroblasts into iPSCs [5, 67]. Sox2, a pluripo-
tency factor that directly binds to Lin28a, has been found to
be critical in regulating Lin28a expression in single-cell gene
expression during iPSCs reprogramming [91, 92]. Overex-
pression of Lin28a can reprogram adult hematopoietic stem
and progenitor cells (HSPCs) into a fetal-like HSPCs, while
Lin28b overexpression can expand neural crest progenitors,
indicating its role in promoting stem cell self-renewal [93,
94].
6. Ubiquitination of Core Reprogramming
Transcriptional Factors
Stem cell transcription factors are highly posttranscription-
ally regulated at the levels of mRNA stability, translation, and
protein stability. Among several different types of posttrans-
lational modifications (PTMs), ubiquitination has emerged
as a major regulator of protein turnover for these core stem
cell transcription factors. Here, we have mapped the lysine
sites present in core stem cell transcription factors that are
predicted to undergo ubiquitination (Figure 4).
6.1. Ubiquitination of Oct3/4. Protein turnover of Oct3/4
is regulated by the ubiquitination process through direct
binding of Wwp2, an E3 ubiquitin ligase, in mouse cells. In
human ES cells, WWP2 targets Oct3/4 for protein degra-
dation [95]. Protein degradation of Oct3/4 is rapid, with a
relatively short half-life of about 90 minutes [96]. Wwp2
promotes both Oct3/4 ubiquitination and degradation to
negatively regulate Oct3/4 transcriptional activity in ES cells
[95]. Oct3/4 was also reported to undergo Lys-63 linked
polyubiquitination and is targeted for protein degradation
through the 26S proteasomal degradation pathway, which
is catalyzed by the mouse E3 ligase Wwp2 [97]. Generally,
poly-Ub chains linked by Lys-63 are not responsible for
protein degradation signaling [98]. However,Wwp2 catalyzes
Lys-63 polyubiquitination of Oct3/4 and these ubiquitinated
Oct3/4 proteins have been tracked to the 26S proteasome for
degradation [97].The action of the E3 ligaseWwp2 onOct3/4
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ubiquitination was well detected during differentiation of
ES cells. Upon treatment of cells with retinoid acid (RA),
Oct3/4 ubiquitinationwas enhanced byWwp2, indicating the
role of Wwp2 in controlling Oct3/4 protein levels during the
RA-induced differentiation process. The action of Wwp2 on
Oct3/4 ubiquitination and degradation is dose-dependent; at
high doses, the enzymatic activity of the E3 ligase is sup-
pressed, due to its own ubiquitination, which occurs through
an intramolecular mechanism. Thus, Wwp2 can control its
own Ub ligase activity by undergoing homodimerization at
higher concentrations and even signalsOct3/4 ubiquitination
during the differentiation of ES cells [97].
Early studies showed that reprogramming efficiency is
dependent on the continued expression of core stem cell tran-
scription factors [99]. Recently, evidence has been growing
that the efficiency of reprogramming is significantly influ-
enced by the expression level of core stem cell transcription
factors [99, 100]. The initiation phase of reprogramming
has been observed in a majority of cells [99]. Interestingly,
most cells then become refractory to reprogramming, with
very few cells eventually progressing to the next phase of
reprogramming. One of the possible reasons for this could
be “innate immunity,” which signals for protein degradation.
Thus, not all cells can be reprogrammed. This phenomenon
can be overcome by additional overexpression of core stem
cell transcription factors [99, 100]. Thus ubiquitination and
the protein expression levels of core transcription factors play
a significant role in cellular reprogramming.
Buckley et al. mapped the ubiquitinated protein land-
scape during ESC differentiation and induced pluripotency
using a shotgun proteomics approach [100]. Additionally,
using a ubiquitin-proteasome system-targeted RNAi screen-
ing method, they identified several regulators involved in the
protein degradation of core stem cell transcription factors.
Among these proteins, Psmd14, Ubr5, and Ddb1 played roles
in regulating ESC self-renewal and pluripotency. Silencing
of these three genes resulted in a significant reduction in
the expression level of the pluripotency marker gene Oct3/4,
coupled with morphological abnormalities in ESCs. Taken
together, ubiquitination and the protein expression level of
Oct3/4 play critical roles in maintaining self-renewal and
reprogramming efficiency.
6.2. Ubiquitination of Klf4. Ubiquitination of Klf4 is an
important posttranslational modification and is responsible
for regulating its protein turnover in the cells. Chen et al.
reported that serum stimulation downregulates Klf4 protein
level [101]. Variations in Klf4 protein levels during serum
stimulation were found to be associated with proteasomal
function and were confirmed through the use of proteasomal
inhibitor MG132. MG132-pretreated cells failed to show a
decrease in Klf4 protein levels upon serum stimulation. Klf4
undergoes rapid protein degradation and has a relatively
short half-life of about 120minutes. MG132-treated cells were
partially refractory to Klf4 protein degradation, resulting in
an extension of its half-life. Ubiquitinated Klf4 conjugates
were observed at a high level in proliferating cells as com-
pared with serum-starved cells, suggesting the importance of
ubiquitination in serum-mediated degradation [101].
Recently, Hu and Wan showed that Klf4 expression was
downregulated in response to TGF-𝛽-signaling, which was
mediated by the ubiquitin-proteasomal pathway (UPP) [102].
The half-life of Klf4 was significantly reduced, suggesting
that TGF-𝛽 enhances Klf4 protein turnover; this finding was
confirmed through the inhibitory effect ofMG132 on TGF-𝛽-
induced Klf4 protein degradation. Furthermore, Cdh1/APC,
a putative E3 ubiquitin ligase, was found to interact with
Klf4 and to regulate TGF-𝛽-induced Klf4 proteolysis. Muta-
tion of the two destruction boxes within Klf4 resulted in
reduced ubiquitination and subsequently resulted in protein
stabilization. Thus, stabilized Klf4 impaired TGF-𝛽-induced
transcriptional activation and further antagonized TGF-𝛽-
induced growth inhibition [102]. Phosphorylation of Klf4was
reported to enhance the ubiquitination and protein degra-
dation of Klf4 [103]. Klf4 phosphorylation by ERK1 recruits
𝛽TrCP1 or 𝛽TrCP2, an F-box protein with E3 ubiquitin ligase
activity, to its N-terminal region and signals for protein
degradation of Klf4 [103]. Thus, treatment with inhibitors of
E3 ligases, such as Cdh1/APC or 𝛽TrCP1, which are known
to interact with Klf4 and trigger protein degradation of
Klf4, might enhance self-renewal capacity and enable Klf4 to
reprogram embryonic fibroblasts more efficiently.
6.3. Ubiquitination of c-Myc. Ubiquitination and proteolysis
of c-Myc are also important posttranslational modifications
regulating the stability and function of c-Myc. Unlike other
defined transcription factors, c-Myc is an unstable protein
exhibiting a half-life of about 20–30 minutes [104]. UPP
is responsible for the degradation of many short-lived reg-
ulatory proteins in vivo [105]. Inhibition of proteasome
activity using different proteasome inhibitors was found to
enhance the stability of the c-Myc protein [106–109]. In this
context, several research groups have examined the domains
or regions responsible for c-Myc ubiquitination and protein
degradation.
Flinn et al. reported that the regions between amino
acids 45 and 63 of Myc Box I (MBI) and amino acids 126
to 144 of MBII are degrons responsible for c-Myc proteolysis
in both yeast and mammalian cells [110]. Salghetti et al.
conducted ubiquitination assays on deletion constructs of c-
Myc and concluded that 128 amino acids in the N-terminal
region contain the Myc degron signal for proteolysis [107].
Indeed, 94 amino acids from the N-terminal region of c-Myc
contribute to destabilization and 147 amino acids from the
N-terminal region of c-Myc result in ubiquitination [107].
In contrast to previous results, Gregory and Hann identified
the primary degrons as consisting of amino acids of 127–
158 of c-Myc and also found that the N-terminal 100 amino
acids are also responsible for c-Myc stabilization, leading to
the prediction that the secondary degron might be located
within the N-terminal 100 amino acids [108]. A deletion con-
struct of c-Myc lackingMBII (c-MycSΔ 106-143) in which the
primary degron lies was also efficiently degraded, suggesting
that the primary degron extends beyond MBII [108]. Thus,
MBI and MBII may serve as binding regions for several
ubiquitin ligases that regulate proteolysis, rather than directly
signaling protein degradation. In addition, a PEST sequence
Stem Cells International 7
between amino acids 226 and 270 was shown to be respon-
sible for rapid c-Myc degradation but did not have any
effect on c-Myc ubiquitination [108]. PEST motif sequences
are enriched in proline (P), glutamic acid (E), serine (S),
threonine (T), and aspartic acid (D) residues and have been
implicated as degradation signals [111, 112]. Several reports
have shown the importance of PEST motifs in tracking
proteins required for the ubiquitin-mediated proteasomal
pathway [112]. It has also been reported that the PEST region
is involved in signaling calpain-mediated proteolysis [113].
Calpain activation induces rapid cleavage of c-Myc in vivo
and in vitro [114], but the relationship between the PESTmotif
of c-Myc and calpain-mediated c-Myc proteolysis has not yet
been determined.
S-phase kinase associated protein (Skp) 2, an F-box pro-
tein in the ubiquitin ligase complex, was the first ubiquitin
ligase for c-Myc identified in yeast cells [115, 116]. Skp2 was
found to interact with multiple regions of c-Myc, mainly
between amino acids 129–147 (MBII) and amino acids 379–
418 [115, 116]. Skp2 significantly enhances the ubiquitination
status of c-Myc, particularly in the region between amino
acids 129–147, which contains one lysine residue (K144) [115].
Additionally, Skp2-mediated ubiquitination of c-Myc has
been shown to regulate c-Myc transcriptional activity. Skp2
was shown to induce a threefold increase in c-Myc transcrip-
tional activity in Gal4 transactivation assays [115]. Skp2 was
also found to induce the 𝛼-prothymosin promoter and cause
a synergistic effect [116]. In turn, Skp2-induced activation of
several promoters requires c-Myc. The interaction between
Skp2 and c-Myc leads to diminished c-Myc protein levels due
to increased c-Myc turnover. In particular, Skp2-mediated c-
Myc turnover was observed at the G1 to S phase transition
during the activation of resting lymphocytes. Apart from the
Skp2 promotion of c-Myc degradation, Skp2 is also involved
in regulating c-Myc’s cellular function by enhancing c-Myc-
induced S phase entry [116].
Fbw7, a component of the SCF ubiquitin ligase complex
containing the F-box substrate recognizing protein, was also
shown to promote c-Myc turnover in vivo and c-Myc ubiq-
uitination in vitro [117]. All three isoforms of the Fbw7
gene (Fbw7𝛼, Fbw7𝛽, and Fbw7𝛾) can negatively regulate
c-Myc turnover. In particular, addition of the proteasomal
inhibitor MG132 reversed c-Myc turnover, suggesting that c-
Myc turnover is proteasome-dependent. Unlike Skp2, Fbw7
decreased c-Myc transcriptional activity in a dose-dependent
manner in c-Myc transactivation assays [117]. Fbw7 binds
with both Thr-58 and Thr-58/Ser-62 doubly phosphorylated
c-Myc peptides and the interaction with Fbw7 that mediates
c-Myc protein turnover is dependent onThr-58 phosphoryla-
tion of c-Myc. In addition, inhibition of GSK3 prevents Fbw7-
mediated c-Myc proteolysis, indicating that Fbw7-driven c-
Myc turnover depends on phosphorylation of c-Myc on
Thr-58 by GSK-3. Thus, Thr-58 phosphorylation-dependent
Fbw7 ubiquitination of c-Myc is not required for c-Myc
transcriptional activity, as was reported for Skp2; instead it
might be involved in c-Myc-mediated apoptosis. Another
study, showed that the region spanning amino acids 127–
189 contains a JNK binding domain and also found that
JNK interactswith c-Myc andpromotes c-Myc ubiquitination
and degradation in vivo and in vitro [118]. Thus, JNK might
associate with other ubiquitin ligases to enhance the ubiqui-
tination and degradation of c-Myc.
6.4. Ubiquitination of Sox2. Recent studies involving large-
scale analyses of phosphorylation in human ES cells have
revealed that Sox2 proteins are phosphorylated. Four poten-
tial phosphorylation sites have been mapped within the Sox2
protein at Ser-246, Ser-249, Ser-250, and Ser-251 [119, 120].
Stabilization of the Sox2 protein upon Sox2 phosphorylation
is in turn regulated by suppression of ubiquitin-mediated
protein degradation. Phosphorylation of Sox2 at Thr-118
enhances protein stability by antagonizing Sox2 protein
degradation; this is not seen when mutant T118A Sox2 is
utilized. Phosphorylation of Sox2 not only promotes Sox2
stability by preventing protein degradation but also enhances
the self-renewal capacity of mouse ESCs, which enables Sox2
to reprogram mouse embryonic fibroblasts more efficiently
[121].
6.5. Ubiquitination of Nanog. Regulation of human Nanog
by UPP was demonstrated by treatment with MG132, a pro-
teasomal inhibitor, which resulted in increased endogenous
ubiquitination of Nanog [122]. In addition, Nanog showed
conjugation with both Lys48- and Lys63-branched polyu-
biquitin chains in vivo. Nanog, which has a PEST motif
sequence from amino acids 47 to 72 at its N-terminal region,
was shown to target proteins for ubiquitination. However,
a PEST motif-deleted Nanog protein was found to be more
stable due to suppression of the ubiquitination process.Thus,
the PEST motif sequence appears to be the signaling factor
in Nanog protein degradation. The level of endogenous
Nanog in human ES cells can be increased by inhibiting
proteasome activity and also by regulating its half-life. Nanog
was reported to have a relatively short half-life of about 120
minutes in human ESCs. Pretreatment of human ESCs with
the proteasome inhibitor MG132 increased Nanog protein
stability and extended its half-life [122]. Thus, fluctuations
in the expression of Nanog in mouse ESCs [87] may be due
to regulation of its protein degradation during pluripotency.
It has been reported that Nanog can be phosphorylated at
four Ser/Thr-Pro motifs, which facilitates the interaction
between Nanog and prolyl isomerase Pin1. As a functional
consequence of the interaction between Nanog and Pin1,
Nanog protein degradation is suppressed, resulting in sta-
bilization of the Nanog protein [123]. Thus, increasing Pin1
activity enhances the capability of Nanog to maintain self-
renewal and enables Nanog to reprogram mouse embryonic
fibroblasts more efficiently.
6.6. Critical Lysine Residues for Protein Stabilization of Core
Stem Cell Transcription Factors. Based on a bioinformatics
analysis, core stem cell transcription factors contain several
predicted ubiquitination sites at lysine residues, as sum-
marized in Figure 4. Replacing the predicted sites of ubiqui-
tination, which are responsible for protein degradation and
transactivation suppression, in the core stem cell transcrip-
tion factors might improve the stability of these proteins
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when used for protein-induced iPSC generation. Despite
some drawbacks, such as difficulties associated with the
purification of stable proteins and low efficiency, the protein-
induced iPSC generation method is very promising for
the production of patient-specific iPSCs. Thus, expression
and purification of modified versions of core transcription
factor proteins with longer half-lives might improve protein-
induced iPSC generation efficiency.
Using this approach, we predicted the lysine sites on the
Klf4 protein potentially responsible for protein degradation
by referring to two bioinformatics databases, UbPred (http://
www.ubpred.org/) andNetChop (http://www.cbs.dtu.dk/ser-
vices/NetChop/). Several Klf4 deletion fragments were ana-
lyzed for ubiquitination and the critical lysine residues
that signal protein degradation were replaced with arginine
residues. Finally, we identified the critical lysine site at
position 232 as being responsible for the high level of ubiq-
uitination. A lysine 232 mutant of Klf4 protein had a longer
half-life and increased protein stability [124]. This mutant
Klf4 protein is being investigated as a way to improve repro-
gramming efficiency.
Given that c-Myc is an unstable protein with a half-life of
about 20–30minutes [104], it is essential to identify the lysine
residue on c-Myc that is responsible for protein degradation.
Taken together, the ability to establish stable core tran-
scription factors without affecting their reprogramming effi-
ciency and the use of these proteins for protein-induced
iPSC generation might be a great contribution to the field of
cellular reprogramming.
7. Deubiquitinating Enzymes Regulating Core
Stem Cell Transcription Factors
The role of posttranslational regulation in stem cell mainte-
nance and cellular reprogramming has been extensively stud-
ied. A key mechanism of posttranslational modification is
ubiquitination by the UPS, which regulates protein turnover
of core stem cell transcription factors. Although several
physiological functions of the UPS in ESC pluripotency
and cellular reprogramming have been reported, there is
limited information on the functions of DUBs in stem cell
maintenance and cellular reprogramming. However, recent
studies on a fewDUBcandidates,mainlyUSP22, Psmd14, and
USP44, have revealed the role of DUBs in regulating stem cell
transcription factors and their influence of the efficiency of
cellular reprogramming.
7.1. USP22. USP22 is a cysteine protease that acts as a tran-
scriptional activator or repressor. USP22 was found to hydro-
lyze monoubiquitin tagged to uH2A and to antagonize PcG
or hydrolyze monoubiquitin from uH2B to regulate MLL-
trithorax-mediated trimethylation of histone H3 lysine-4
[125–129]. Recently, several lines of evidence have proven that
USP22 plays a major role in stem cell function.USP22 can be
considered a cancer stem cell marker gene due to its activity,
which facilitates aggressive cellular phenotypes, including
metastatic potential and resistance to therapy [130, 131]. The
USP22 locus has been found to be actively transcribed in both
human ESCs and iPSCs. Additionally, the histone H3 lysine-
4 trimethyl epigenetic marker is recruited to the USP22
promoter, which is also occupied by the core pluripotency
factor KLF4, suggesting its role in stem cell pluripotency
and differentiation [132]. USP22 has also been shown to be
essential for embryonic development in mice [131].
Recent evidence has revealed that USP22 regulates core
pluripotency factors, including c-Myc and Sox2. USP22 was
identified as an essential cofactor for the stem cell transcrip-
tion factor Myc in the regulation of transcription of Myc
target genes [128]. Sussman et al. showed that USP22 is
induced as the differentiation process of ESCs progresses.The
expression level of USP22 is critical during ESC differenti-
ation; its ectopic expression can trigger differentiation even
in the absence of other differentiation signals. Depletion of
USP22 resulted in defects in the transcription of genes related
to all three germ layers, indicating its requirement for proper
ESC differentiation into all three germ layers [133]. During
ESC differentiation, USP22 acts as a transcriptional repressor
of the Sox2 locus. USP22 has been found to be located directly
on the Sox2 promoter and catalyzes deubiquitination of H2B
and attenuates Sox2 transcription. By contrast, depletion of
RNF20, the E3 ligase of H2B, opposes the effect of USP22 on
Sox2 transcription [133]. Thus, USP22 plays a pivotal role in
the efficient differentiation of ESCs by repressing Sox2 and
allowing ESCs to transition from a state of self-renewal to
lineage-specific differentiation pathways.
7.2. Psmd14. Psmd14 was initially identified as a component
of the 19S proteasome lid [134]. Psmd14 is highly expressed
in pluripotent ESCs, whereas its expression level decreases
significantly upon differentiation. Psmd14 was one of the
DUB candidates identified along with USP9X when UPS-
targeted siRNA screening was performed to identify genes
required to maintain ES cell self-renewal and pluripotency
[100]. Depletion of Psmd14 leads to a significant decrease
in Oct4 protein expression coupled with abnormal ESCs
morphology. Psmd14 was found to interact with the majority
of the 19S proteasome lid, including Psmd3, Psmd6, Psmd7,
Psmd11, Psmd12, and Psmd13, in ESCs. Depletion of Psmd14
did not alter the overall stoichiometry of the 26S proteasome
as no significant changes were observed in the expression
of its interacting partners or in the components of the pro-
teasome lid. However, there was a defect in proteasome activ-
ity leading to accumulation of both K48- and K63-linked
polyubiquitinated proteins. In addition, there was a loss
of Oct3/4 expression and morphological changes consistent
with ES differentiation. Finally, Psmd14 expression was found
to be absolutely essential for generating iPSCs.When Oct3/4,
Klf4, Sox2, and c-Myc expressing MEFs were transduced
with virus expressing shRNAs against Psmd14, the MEFs
expressing Psmd14 shRNAs failed to reprogram and generate
iPSCs [100]. Thus, Psmd14 is strongly considered to be an
important candidate required for iPSC generation.
7.3. Other DUBs. Based on genome-scale location analysis,
several DUBs have been reported to play roles in transcrip-
tional regulation of human embryonic stem cells. These
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DUBs bind to the promoter regions of core embryonic
transcription factors, such as Oct4, Sox2, and Nanog [135].
USP44 and USP7 were found to bind to the Oct4 promoter.
USP25, USP44, USP49, and USP7 bind to the Sox2 promoter,
while USP10, USP16, USP3, USP37, USP44, and USP7 bind
to the Nanog promoter. In addition, USP9X was also found
in mouse and human stem cells, including embryonic and
neural stem cells or neuronal progenitors, hematopoietic
stem cells, and adult epidermal stem cells [136, 137]. However,
the mechanism of Oct4, Sox2, and Nanog protein regulation
byDUBs and their role in stem cell differentiation and cellular
reprogramming remains unidentified.
Recently, the functions of USP7 and USP44 were linked
to stem cell maintenance and differentiation [138, 139]. REST
is a stem cell transcription factor and its protein level is crit-
ical during neural differentiation. USP7 interacts and sta-
bilizes the REST protein by blocking SCF𝛽-TrCP-mediated
ubiquitination, thereby promoting the maintenance of stem-
ness [138]. USP44 acts as a negative regulator of H2B ubiqui-
tination during stem cell differentiation. Depletion of USP44
results in an increase inH2B ubiquitination, whereasmonou-
biquitination of H2B is known to increase during stem cell
differentiation, suggesting that an optimum expression level
of USP44 is required for ESC differentiation [139].
8. Conclusions
A growing body of evidence has proven that core stem cell
transcription factors regulating ESC self-renewal and stem
cell maintenance, such as Oct3/4, c-Myc, Sox2, Klf4, and
Nanog, are ubiquitinated by several different E3 ubiquitin
ligases. Indeed, E3 ligases have been shown to have a negative
influence during the generation of iPSCs by mediating
protein degradation of core transcription factors. Based on
recent reports, it is likely that each stem cell transcription
factor can be deubiquitinated by specific DUBs. Thus, stem
cell transcription factors are regulated by both ubiquitination
and deubiquitination at the posttranslational level.Therefore,
identification of the DUBs that reverse the proteolysis of stem
cell transcription factors will be important to our under-
standing of the molecular mechanisms of cell fate determi-
nation of ESCs.
Balanced control over the ubiquitination and deubiquiti-
nation processes of stem cell transcription factors determines
the fate of the stem cells with respect to differentiation or
the maintenance of pluripotency. Ubiquitination of stem cell
transcription factors by E3 ligases results in stem cell differ-
entiation, while activation of DUBs prevents proteolysis by
stabilizing stem cell transcription factors and promoting stem
cell maintenance (Figure 5). As suggested by the available
data, methods to control the action of E3 ubiquitin ligases on
stem cell transcription factors during cellular reprogramming
might improve the reprogramming efficiency. One possible
way of blocking the interaction between E3 ubiquitin ligases
and stem cell transcription factors would be to use protein
inhibitors that specifically target the E3 ubiquitin ligases
for the stem cell transcription factors utilized during the
cellular reprogramming process. Alternatively, we can screen
for potential DUBs that regulate the protein levels of core
Protein 
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Stem cells 
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Stem cells 
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Figure 5: Schematic representation of the roles of E3 ligases and
deubiquitinating enzymes in regulating stem cell differentiation and
stemcellmaintenance.Ubiquitination of core stem cell transcription
factors by E3 ligases mediates stem cell differentiation. Deubiquiti-
nation of the core stem cell transcription factors by DUBs mediates
stem cell maintenance.
stem cell transcription factors. Delivering a combination of
potential DUBs that regulate protein turnover of stem cell
transcription factors along with the core transcription factors
during cellular reprogramming might enhance the efficiency
of cellular reprogramming. Taken together, utilizing this
paradigm of reciprocal posttranslational control by DUBs in
stem cell regulatory networks during iPSC generation might
significantly improve cellular reprogramming efficiency,
thereby leading to an advanced and novel route for cellular
reprogramming.
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